Retrospective analyses of patient characteristics having predictive impact on survival under everolimus

Onkologie

Volumn 34, Issue 3, 2011, Pages 111-114

  Seidel, Christoph ^a   Fenner, Martin ^a   Reuter, Christoph ^a   Merseburger, Axel S ^a   Ganser, Arnold ^a   Grünwald, Viktor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Everolimus; mTOR inhibition; Prognostic factor; Renal cell cancer; Systemic therapy

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SIROLIMUS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952261723     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324668     Document Type: Article

References (11)

1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial. Lancet 2008;372:449-456.
2. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation initiation and cancer. Oncogene 2006;25:64166422.
3. Corradetti MN, Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006;25:6347-6360. (Pubitemid 44582281)
4. Motzer RJ, Hutson T, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
5. Shepard DR, Rini BI, Garcia JA, Hutson TE, Elson P, Gilligan T, Nemec C, Lopez R, Borner D, Dreicer R, Bukowski RM: A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; (suppl);abstr 5123.
6. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP: A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-2446.
7. Rini BI, G. T. W., Hudes G, Stadler WM, Kim S, Tarazi JC, Bycott PW, Liau KF, Dutcher JP: Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 2007; 25(suppl 18S):abstr 5032.
8. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T: mTOR inhibitor RAD001 (everolimus) has antiangiogenic/ vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15:1612- 1622.
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
10. Cho KS, Choi YD, Kim SJ, Kim CI, Chung BH, Seong do H, Lee DH, Cho JS, Cho IR, Hong SJ: A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J 2008;49:451-458.
11. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM: Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. Cancer 2007;110:543-550. (Pubitemid 47106142)